en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
5/2008
vol. 46
 
Share:
Share:
more
 
 
abstract:

Review papers
Indication for the use of TNF-α blockers in ankylosing spondylitis – comparison of different published recommendations

Ewa Stanisławska-Biernat

Reumatologia 2008; 46, 5: 272-277
Online publish date: 2008/12/01
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Ankylosing spondylitis is a chronic inflammatory disease with young age onset which after years of duration leads to spinal stiffness, loss of function, disability, as well as a considerable percentage of work-incapacitated patients. The efficacy of a new group of drugs – TNF blockers – has been confirmed in many randomized clinical trials, the results of which have published over the last several years. The introduction of TNF blockers has caused a revolution in rheumatology. International groups of experts and scientific rheumatology societies from different countries, including Poland, have published treatment guidelines, which are regularly revised and updated. This article analyzes similarities and differences between ASAS, British, French, Canadian and Polish recommendations for the management of ankylosing spondylitis as well as prescribing and monitoring of TNF-α antagonist therapy.
keywords:

ankylosing spondylitis, treatment, biologic treatment, TNF-α blockers, recommendations







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.